We showed that Th17-mediated inflammation was ameliorated in NQO1-deficient EAE model (Fig 3), indicating that inhibition of NQO1 by specific inhibitor such as dicoumarol could be a potential candidate for the therapeutic treatment against autoimmune diseases such as multiple sclerosis. This evidence concerns the gene NQO1 and autoimmune disease.